Benitec Biopharma Inc (BNTC) — Who Owns This Stock? 13F Breakdown (Q2 2026)

BNTC ranks #4859 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

89 institutions disclose a position in BNTC, but none treat it as a major bet — even Lion Point Capital, LP, its most concentrated holder, allocates just 4.0% of its own portfolio to it.

BNTC is down 4.1% today, but institutions show net buying of $17.0M this quarter — a divergence between today's price move and the underlying institutional flow.

BNTC reported a net loss of $45.5M over the trailing twelve months.

• Not yet profitable — net loss of $45.5M over the trailing twelve months
• Net income declined year over year, from -$45.3M to -$45.5M
• Operating cash flow was negative, using $16.5M in cash
• Current ratio of 34.00x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.03x equity — within a conventional range